Sepsis is one of the most common causes of morbidity and mortality in the newborn. Early diagnosis and treatment is vital to improve outcome. Investigate the possible role for endocan in the diagnosis of neonatal early onst sepsis. 40 children were included in the study, 20 septic and 20 controls, all patients were subjected to full history and clinical assessment and labouratory tests as CBC, CRP and serum level of endocan by ELISA. Results: Neonatal Sepsis group showed significantly higher Endocan when compared to control group (p < 0.001),ROC curve of Endocan level was conducted for discrimination between neonatal sepsis cases and control groups. Endocan showed AUC (AUC=0.758). At cut off value of 21.4, sensitivity was 70%, specificity was 78.3%, PPV was 74.5%, NPV was 68.1%, accuracy was 70.8%. Serum endocan levels are significantly increased in septic compared to non-septic neonates in the early stages of sepsis. We suggest that endocan is an effective, reliable, and promising new biomarker for detecting neonatal sepsis.